Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets
Tourmaline Bio’s experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study.
The company must now show the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
